Wu K K, Barnes R W, Hoak J C
Circulation. 1976 Apr;53(4):687-91. doi: 10.1161/01.cir.53.4.687.
Studies of platlet function were performed in 30 patients with idiopathic recurrent venous thrombosis. Evidence of platelet hyperactivity was found in 14 patients who exhibited spontaneous platelet aggregation and in 13 patients who had evidence of circulating platelet aggregates. No other differences in clinical characteristics or coagulation parameters could be elucidated between these two subgroups. In nine patients who had 51Cr-labeled platelet survival studies, there was a good correlation between the platelet hyperactivity and shortened platelet survival. Spontaneous platelet aggregation was inhibited both in vivo and in vitro by aspirin. In addition, the circulating platelet aggregates were normalized by combination treatment with aspirin and dipyridamole. The results indicate that the idiopathic recurrent venous thrombosis patient population could be differentiated by the platelet function tests into subgroup I, in which no platelet abnormality could be detected, and subgroup II, where platelet hyperaggregability was present. These results indicate that the role of platelets should be considered in the pathogenesis of recurrent venous thrombosis and therapy with agents which inhibit platelet aggregation may be beneficial in the patients with platelet hyperaggregability.
对30例特发性复发性静脉血栓形成患者进行了血小板功能研究。在14例出现自发性血小板聚集的患者和13例有循环血小板聚集体证据的患者中发现了血小板活性亢进的证据。这两个亚组之间在临床特征或凝血参数方面没有发现其他差异。在9例进行了51Cr标记血小板存活研究的患者中，血小板活性亢进与血小板存活时间缩短之间存在良好的相关性。阿司匹林在体内和体外均能抑制自发性血小板聚集。此外，阿司匹林和双嘧达莫联合治疗可使循环血小板聚集体恢复正常。结果表明，特发性复发性静脉血栓形成患者群体可通过血小板功能测试分为亚组I（未检测到血小板异常）和亚组II（存在血小板高聚集性）。这些结果表明，在复发性静脉血栓形成的发病机制中应考虑血小板的作用，对于血小板高聚集性患者，使用抑制血小板聚集的药物进行治疗可能有益。
